(Circulation. 1999;100:178-184.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Simvastatin Preserves the Ischemic-Reperfused Myocardium in Normocholesterolemic Rat Hearts
From the Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pa, and the Department of Molecular and Cellular Physiology, Louisiana State University Medical Center, Shreveport (D.J.L.).
Correspondence to Dr Allan M. Lefer, Department of Physiology, Jefferson Medical College, Thomas Jefferson University, 1020 Locust St, Philadelphia, PA 19107-6799.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Ischemia followed by reperfusion in the presence of polymorphonuclear leukocytes (PMNs) results in cardiac contractile dysfunction as well as cardiomyocyte injury. These deleterious effects are due in large part to endothelial dysfunction leading to the upregulation of cell adhesion molecules and subsequent neutrophil-endothelium interaction. At clinically relevant doses, simvastatin, an HMG-CoA reductase inhibitor, has been shown to lower serum cholesterol levels and normalize endothelial cell function. We wanted to test the effects of simvastatin on neutrophil-mediated cardiac dysfunction in a controlled model of myocardial ischemia-reperfusion.
Methods and Results—This study examines the effects of simvastatin in a neutrophil-dependent isolated perfused rat heart model of ischemia (I) (20 minutes) and reperfusion (R) (45 minutes) injury. Administration of simvastatin 25 µg/rat improved coronary flow and preserved left ventricular developed pressure (LVDP) and dP/dtmax, indexes of cardiac contractile function. Final LVDP was 95±5 mm Hg in I/R hearts perfused with PMNs and simvastatin, compared with 49±4 mm Hg in PMN-perfused I/R hearts receiving only vehicle (P<0.001). In addition, simvastatin significantly reduced PMN accumulation in the ischemic myocardium (P<0.01). In PMN-perfused rat hearts after I/R, simvastatin also significantly attenuated P-selectin expression, CD18 upregulation in rat PMNs, and PMN adherence to rat vascular endothelium. Significant, although less potent, effects were obtained with pravastatin.
Conclusions—These results provide evidence that HMG-CoA reductase inhibitors are potent and effective cardioprotective agents that inhibit leukocyte–endothelial cell interactions and preserve cardiac contractile function and coronary perfusion after myocardial ischemia and reperfusion. Moreover, these effects are unrelated to the cholesterol-lowering action of this agent and appear to be mediated by enhanced endothelial release of NO.
Key Words: simvastatin • ischemia • reperfusion • myocardium • leukocytes
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Prompt and effective reperfusion of the ischemic myocardium plays an important role in minimizing cardiomyocyte injury associated with acute myocardial ischemia. However, myocardial reperfusion itself results in enhanced myocardial injury.1 2 The process of reperfusion injury is characterized by an inflammatory response in which polymorphonuclear leukocytes (PMNs) play an important role.2 3 On reperfusion, many activated PMNs accumulate in the coronary microvasculature and infiltrate into the myocardium.4 5 Activated PMNs can stimulate tissue injury by the release of a variety of cytotoxic substances, including oxygen-derived free radicals, inflammatory cytokines, and proteases.6 Many of these substances also mediate vascular endothelial dysfunction as well as myocardial cell injury.7 This process is also consistent with evidence that either decreasing the number of circulating PMNs or administration of monoclonal antibodies directed against neutrophil- or endothelial cell–derived adhesion molecules leads to significant cardioprotection in the setting of reperfusion injury.8 9 10 11 At present, there is no standard therapy for reperfusion injury that is widely accepted in the field. Moreover, myocardial ischemia in humans is often brought about by the long-term consequences of hypercholesterolemia (ie, endothelial dysfunction, plaque formation, fissures in arterial plaques, etc).12 Against this setting, cholesterol-lowering agents have been widely used to reduce cardiovascular risk.13 14 15 The major action of the HMG-CoA reductase inhibitors (eg, simvastatin, pravastatin, etc), collectively known as the "statins," is inhibition of cholesterol synthesis in the liver.16 Recently, however, there has been a suggestion that these statins may exert effects separate from their cholesterol-lowering actions, including promotion of endothelial NO synthesis.17 We therefore tested the hypothesis that a clinically relevant dose of a widely used statin could exert an ameliorating effect on reperfusion injury in a neutrophil-dependent model of myocardial ischemia-reperfusion.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Isolated Rat Heart Preparation
Male Sprague-Dawley rats (270 to 320 g) were anesthetized with 60 mg/kg sodium pentobarbital, and sodium heparin 1000 U IP was administered (Elkins Sinn). Hearts were rapidly excised, the ascending aorta was cannulated, and retrograde perfusion of the nonworking heart was initiated with a modified Krebs buffer maintained at 37°C and at a constant pressure of 80 mm Hg. The Krebs buffer had the following composition (in mmol/L): glucose 17, NaCl 120, NaHCO3 25, CaCl2 2.5, EDTA 0.5, KCl 5.9, and MgCl2 1.2. The perfusate was aerated with 95% O2/5% CO2, which was equilibrated at a pH of 7.3 to 7.4. Two side arms of the apparatus in the perfusion line just proximal to the heart inflow cannula allowed the infusion of PMNs and plasma directly into the coronary inflow line. To assess cardiac contractile function, a 2.5F microtip catheter transducer (Millar Instruments) was inserted directly into the left ventricular cavity, as previously described.18 19 The left ventricular pressures, the maximal rate of development of left ventricular developed pressure (+dP/dtmax), and coronary flow were all recorded with a MacLab data acquisition system (ADI Diagnostics) in conjunction with a Power Macintosh 7600 computer (Apple Computers). All of these data were stored and analyzed at the end of each experiment.
After the first 15 minutes of perfusion, baseline left ventricular developed pressure (LVDP), +dP/dtmax, and coronary flow were measured every 5 minutes for 15 minutes to ensure complete equilibration of the hearts. LVDP was defined as left ventricular end-systolic minus left ventricular end-diastolic pressure. In all of the hearts, at both the initial and final readings, end-diastolic pressure was 4 to 8 mm Hg. The first derivative of left ventricular pressure (+dP/dtmax) was recorded from instantaneous left ventricular pressure. Flow of the Krebs buffer was then reduced to zero, creating a state of total global ischemia. This ischemia was maintained for 20 minutes. The flow was then allowed to return to values near control levels by reestablishment of coronary perfusion pressure at 80 mm Hg. At reperfusion, 100x106 PMNs and 5 mL of plasma were infused directly into the coronary circulation over a period of 5 minutes via a set of side ports situated just proximal to the heart in the perfusion line. The PMNs were suspended in 5.0 mL of Krebs buffer in a syringe. Rat plasma was also placed into a different 5.0-mL syringe located just proximal to the inflow port to the coronary circulation. The hearts were allowed to reperfuse for a total of 45 minutes, during which time the data were collected every 5 minutes. Rats were given 25 µg simvastatin or pravastatin IP in 0.9% NaCl or saline alone 18 hours before isolation of the hearts. Simvastatin and pravastatin were prepared fresh from powder, dissolved in 0.9% NaCl, and stirred for 4 hours before injection to facilitate solubilization. In some experiments, hearts were isolated from statin-treated rats and perfused with normal nontreated PMNs, and in other experiments, PMNs were isolated from statin-treated rats and perfused into normal nontreated hearts.
Isolation of PMNs and Plasma
Sprague-Dawley rats (350 to 400 g) were
anesthetized with pentobarbital sodium 60 mg/kg IP. PMNs were
isolated from rat blood by the method of Williams et al20
using the hetastarch exchange transfusion method. This method
yielded 110x106 to
130x106 PMNs per rat, which were >95% pure and
>95% viable. These PMNs were washed 5 or 6 times to remove the
hetastarch before perfusion into rat hearts according to previously
described procedures.20
Blood from nontreated rats was centrifuged immediately in a refrigerated centrifuge at 2000g for 10 minutes, and the plasma was decanted. The plasma was infused along with the PMNs to more closely simulate the conditions present in vivo. In several rats, plasma was used for total cholesterol determination spectrophotometrically with Sigma Diagnostics reagents.
Determination of Neutrophil Infiltration of Cardiac Tissue
In several additional hearts, 6
ischemic–vehicle-reperfused and 6 ischemic hearts
isolated from rats given 25 µg simvastatin at
reperfusion, histological sections were made according
to previously described techniques for the counting of infiltrating
PMNs.19 All neutrophil counts were determined without
prior knowledge of the group from which each sample originated.
Quantification of CD18 Expression on Rat Isolated
Neutrophils
Flow cytometric analysis of CD18 expression on the cell
surface of freshly isolated rat neutrophils was performed according to
standard procedures.21 Rat neutrophils were freshly
isolated from rat whole blood according to the method of Williams et
al.20 Isolated neutrophils were washed twice in
calcium-free Tyrode's solution containing 0.2% BSA and suspended in
PBS. Neutrophils (5x105 cells/tube) were
incubated with anti-CD18 antibody (Wt. 3, Endogen) (4°C for 60
minutes). Excess primary antibody was then removed by washing of
neutrophils in D-PBS. A goat anti-human IgG F(ab')2 FITC-conjugated
antibody was used as the secondary antibody at a 1:100 dilution (4°C
for 30 minutes). The stained neutrophils were washed twice with DPBS
and finally fixed in 1% paraformaldehyde, and then
analyzed by flow cytometry (FACScan, Becton-Dickinson).
Immunohistochemistry of P-Selectin Expression
Immunohistochemistry for P-selectin was performed on tissue
sections embedded in plastic (Immunobed; Polysciences Inc) according to
previously described techniques.22 The basic method used
was the avidin-biotin immunoperoxidase technique with monoclonal
antibody PB1.3 as the monoclonal antibody directed against P-selectin.
Positive staining was defined as a coronary microvessel
displaying brown reaction product on >50% of the circumference of
its endothelium. Fifty vessels per tissue sample were
examined in each of 3 hearts per group.
Neutrophil Adherence to Superior Mesenteric Artery
Endothelium
Rat neutrophils were isolated as reported above. Segments of the
superior mesenteric artery (SMA) were removed from control rats and
simvastatin-treated rats, sectioned into 2- to 3-mm rings,
opened, and placed into wells containing 2 mL Krebs-Henseleit (K-H)+2%
BSA solution. The SMA tissue was challenged with 2 U/mL thrombin (Sigma
Immunochemicals) to induce P-selectin surface expression on the
endothelium and coincubated with labeled PMNs
(106), as previously described.19
The number of adherent PMNs was counted by epifluorescence
microscopy. Five different fields of each endothelial
surface were counted, and the results are expressed as adherent
PMNs/mm2 of endothelium.
Effect of Simvastatin on NO Release From Isolated Rat
Aortic Segments
We used freshly isolated rat aortic rings as the source of
primary endothelial cells. Thoracic aortas isolated
from control rats and simvastatin-treated rats were
immersed in warm oxygenated K-H solution and cleaned of
adherent fat and connective tissue. Aortic rings 6 to 7 mm long
were carefully cut, opened, and fixed by small pins with the
endothelial surface up in culture dishes containing 1
mL K-H solution. After equilibration at 37°C, NO released into the
K-H solution was measured with a polarographic NO electrode (Iso-NO,
World Precision Instruments, Inc) according to the method of Guo et
al.23 Calibration of the NO electrode was performed daily
before each experimental protocol. A standard calibration curve was
obtained by graded concentrations of KNO2 at 0,
5, 10, 25, 50, 100, 250, and 500 nmol/L (final concentrations) into a
calibration solution containing 0.1 mol/L KI and 0.1 mol/L
H2SO4.
Statistical Analysis
All data in the text and figures are presented as
mean±SEM. The data on left ventricular function and
coronary flow were analyzed by ANOVA incorporating
repeated measures. Other data were compared by an ANOVA using post hoc
analysis with Fisher's corrected t test.
Probability values of 
0.05 were considered to be statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To determine whether clinically relevant doses of simvastatin can attenuate leukocyte-endothelium interactions and improve cardiac contractile function in acute myocardial ischemia-reperfusion, we perfused nonischemic control rat hearts for 80 minutes at 80 mm Hg at a control flow of 20 to 25 mL/min or for 15 minutes at control flow followed by 20 minutes of total global ischemia and 45 minutes of reperfusion at control flows either with or without PMNs and plasma. Perfusion of additional simvastatin-treated hearts was also performed at a perfusion pressure of 80 mm Hg for 80 minutes. Perfusion of simvastatin-treated hearts at 80 mm Hg during sham ischemia or during ischemia-reperfusion without PMNs did not result in any change in coronary flow, LVDP, or dP/dtmax at the end of the observation period, indicating that simvastatin did not exert any direct cardiodynamic effect. Furthermore, perfusion of untreated nonischemic hearts with PMNs did not alter any of the cardiac function variables measured, indicating that PMNs did not provoke cardiac dysfunction in normal nonischemic hearts. Only ischemic-reperfused rat hearts perfused with PMNs experienced a marked reduction in cardiac contractile function and coronary flow.
Ischemic-reperfused hearts perfused with PMNs and plasma
exhibited significant cardiac dysfunction (P<0.01). Thus,
coronary flow was decreased 27±3% (P<0.05) from
initial values (Figure 1
), LVDP decreased
51±4% from initial values (P<0.01) (Figure 2), and dP/dtmax
decreased 58±4% from initial values (P<0.01) (Figure 3). This decrease in coronary
flow and marked reduction in cardiac contractility can
be attributed largely to the presence of PMNs at the time of
reperfusion. This cardiac dysfunction is therefore due to the
interaction of PMNs with the coronary microvascular
endothelium. Against this background,
simvastatin, given to rats 18 hours before isolation of the
heart and subsequent induction of ischemia-reperfusion,
markedly attenuated all 3 components of the cardiac dysfunction. Thus,
simvastatin prevented the coronary flow deficit and
enhanced LVDP and dP/dtmax at the end of the
reperfusion period whether hearts or only PMNs were used from
simvastatin-treated rats (Figures 1, 2, and 3). Because no increase in coronary flow, LVDP, or
dP/dtmax occurred in nonischemic controls
in the presence or absence of PMNs, these cardioprotective effects are
not due to direct cardiodynamic effects of the simvastatin.
Moreover, these salutary effects are unrelated to the
cholesterol-lowering effect of simvastatin,
because plasma cholesterol was 38±5 mg/dL in 5 control
rats, 44±3 mg/dL in 5 simvastatin-treated rats, and 47±5
mg/dL in 5 pravastatin-treated rats.
|
|
|
Five additional hearts treated with 25 µg pravastatin and 5 with saline were subjected to the same ischemia-reperfusion protocol with PMNs as was the simvastatin group. The pravastatin-treated hearts responded significantly, although somewhat less than the simvastatin-treated hearts. Thus, final LVDP was 52±3 versus 88±3 mm Hg (P<0.01) in saline- versus pravastatin-treated hearts, compared with 102±4 mm Hg initially. This corresponds to an 86% recovery versus a 97% recovery in simvastatin-treated hearts. Similarly, final +dP/dtmax was 2188±184 versus 3428±177 in saline- versus pravastatin-treated hearts (P<0.02), compared with 4464±215 initially. This corresponds to a 77% recovery compared with a 97% recovery in simvastatin-treated hearts.
Because the cardiac dysfunction appeared to be due to the
cardiodepressant actions of neutrophils on a sensitized
ischemic-reperfused coronary microvasculature, we
studied this interaction further. The first questions to be asked were:
Do neutrophils infiltrate into the ischemic-reperfused rat
heart? and Does simvastatin have any effect on this
neutrophil infiltration? Histological counting of PMNs
was used to assess PMN infiltration. Figure 4 summarizes the PMN infiltration data in
these perfused rat hearts. None of the nonischemic control rat
hearts or any of the ischemic-reperfused rat hearts perfused
without PMNs exhibited any significant cardiac PMN infiltration. In
contrast, ischemic-reperfused hearts perfused with PMNs
exhibited an 8-fold increase in PMNs/mm2 of heart
area (P<0.01), indicative of significant PMN infiltration
into these hearts. However, when either PMNs or hearts were isolated
from simvastatin-treated rats and subjected to
ischemia-reperfusion with PMNs, significantly lower numbers of
infiltrated PMNs were observed.
|
To determine whether the endothelium of
simvastatin-treated rats exhibited any changes in adhesion
molecule expression that could account for the low degree of PMN
involvement, we performed immunohistochemical analysis of
P-selectin expression on the rat coronary microvascular
endothelium. Figure 5
summarizes these results. Nonischemic controls exhibited very
low P-selectin surface expression on the coronary
endothelium. However, untreated rat hearts subjected to
ischemia and reperfused with PMNs developed a 6-fold increase
in P-selectin surface expression. This was markedly attenuated
(P<0.01) in ischemic-reperfused rat hearts whether
or not the hearts or the PMNs were isolated from
simvastatin-treated rats.
|
To determine whether simvastatin can moderate
P-selectin–mediated PMN adherence to the endothelium,
we studied PMN adherence to isolated vascular segments obtained from
control or simvastatin-treated rats. Figure 6 summarizes these results. Thrombin was
used to upregulate P-selectin expression on the
endothelium. Vascular segments stimulated with thrombin
2 U/mL exhibited a 9-fold increase in PMN adherence
(P<0.001). This was totally blocked by a monoclonal
antibody that neutralized P-selectin. Moreover, in experiments using
either blood vessels or PMNs isolated from
simvastatin-treated rats, adherence was significantly
attenuated. Thus, simvastatin exerts an antiadherence
effect both on PMNs and on the endothelium. This
antiadherence effect could be a major factor contributing to the
cardioprotection observed in simvastatin-treated
hearts.
|
Because the adherence studies suggested that at least part of the
simvastatin effect was on neutrophils, we studied further
the effect of simvastatin on PMN expression of the
neutrophil surface adhesion molecule CD18 via flow cytometry. Figure 7 illustrates a
representative flow cytometry histogram. Unstimulated
PMNs taken from control untreated rats exhibited a normal distribution.
Stimulation of control rat PMNs with 100 nmol/L leukotriene
B4 (LTB4) induced a marked
shift to the right of the PMNs characteristic of activation. However,
PMNs isolated from simvastatin-treated rats given
LTB4 remained largely unactivated,
suggesting that simvastatin also exerts an antineutrophil
effect that may be important in curtailing
PMN-endothelium interaction.
|
), LTB4-stimulated PMNs from control
rats (
), and LTB4-stimulated PMNs from
simvastatin-treated rats (
) were incubated
with anti-CD18 monoclonal antibody and labeled with a secondary
antibody. Simvastatin clearly attenuated LTB4
upregulation of CD18 in rat PMNs.
To test whether the cardioprotective effects of simvastatin
were due to increased bioavailability of NO, we measured NO release
from aortic segments isolated from both vehicle- and
simvastatin-treated rats. We detected a small basal level
of NO release in the range of 20±4 nmol/g tissue in aortic rings
isolated from vehicle-injected rats (Figure 8). However, 18 hours after rats were
given 25 µg simvastatin, the basal release of NO measured
in aortic rings doubled (P<0.01). Moreover, the addition of
an NO synthase (NOS)–inhibiting concentration of
N
-nitro-L-arginine
methyl ester (ie, 100 µmol/L) inhibited NO release in aortic
rings obtained from both vehicle-treated and
simvastatin-treated rats (Figure 8). Therefore,
systemic administration of simvastatin to the rats
significantly increases endothelium-derived NO.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
It is well known that hypercholesterolemia, even in the absence of plaque formation, results in endothelial dysfunction.24 25 This endothelial dysfunction is characterized by a reduction in biologically active NO released from the endothelium. Whether this is due to an absolute reduction in endothelium-derived NO or in part to rapid quenching of NO by superoxide radicals remains to be clarified.26 In any event, moderate degrees of hypercholesterolemia do not physically injure the endothelium or induce its sloughing.27 28 Furthermore, increased plasma cholesterol levels in rabbits in the absence of atherosclerotic plaque formation has been shown to exacerbate reperfusion injury after myocardial ischemia.29 One widely used means of controlling hypercholesterolemia is HMG-CoA reductase inhibitors, the statins. This is because they inhibit hepatic biosynthesis of cholesterol at the mevalonate step.16 This reduced cholesterol synthesis results in reduced coronary artery disease14 30 and stroke.15 Moreover, statins have been found to restore endothelial function toward normal in animals31 and humans.12 13 14 These effects are presumed to be due directly to reduced cholesterol synthesis, leading to reduced cholesterol droplets in endothelial cells and therefore to preservation of endothelial function, including maintenance of NO release.
The present findings clearly point toward an action other than cholesterol lowering for the statins. In this study, either simvastatin or pravastatin given 18 hours before induction of myocardial ischemia exerted a marked cardioprotective effect of dramatically blunting reperfusion injury. The data also suggest that statins attenuated neutrophil-endothelium interaction in the coronary microvasculature. Several possibilities may explain the cardioprotective effects of statins at normal cholesterol levels. These mechanisms all relate to preservation of endothelial function, inhibition of neutrophil activation, or a combination of the two effects.
With regard to neutrophil function, it is known that
lovastatin reduces monocyte CD11b expression and monocyte
adhesion to the endothelium in patients32
independently of its cholesterol-lowering effect. CD11b is
the 
-chain of the ß2-integrins, which
participates in an important way in promoting firm adhesion of
leukocytes to the endothelium. In our studies, we
assessed the common ß-chain of the
ß2-integrins, CD18, in rat neutrophils.
Simvastatin clearly attenuated LTB4
upregulation of CD18. Moreover, statins significantly inhibited
neutrophil and monocyte chemotaxis in human blood cells.33
This effect could partially explain the results obtained in the
present study. Thus, there is evidence that the statins may exert
anti-inflammatory actions on blood cells in the absence of
hypercholesterolemia.
A second and perhaps related effect of the statins may be upregulation of endothelial NO synthesis34 as well as inhibition of hypoxia-mediated inhibition of NOS activity.35 Maintenance of endothelium-derived NO may be a very important aspect of the cardioprotective effects of simvastatin. NO exerts a variety of important homeostatic actions that could help explain these results. NO has been shown to act as a physiological inhibitor of leukocyte–endothelial cell interaction36 by suppressing upregulation of several endothelial cell adhesion molecules, including P-selectin,37 VCAM-1, and ICAM-1.38 NO is able to inhibit neutrophil-induced cardiac dysfunction by preserving endothelial release of NO. Similar salutary effects were observed with simvastatin and lovastatin in mice subjected to cerebral ischemia-reperfusion.39 These effects were dependent on enhanced NO formation, because they did not occur in endothelial constitutive NOS knockout mice,39 and were unrelated to the inhibitory effect of simvastatin on cholesterol biosynthesis. Moreover, this endothelial preservation with its subsequent attenuation of neutrophil activation effectively prevents neutrophil-induced cardiac dysfunction. In this regard, we have presented new evidence showing that simvastatin significantly increases basal NO release from the vascular endothelium by a specific mechanism involving NOS. This increased bioavailability of NO is likely to attenuate P-selectin upregulation on the coronary microvascular endothelium, thus limiting neutrophil adherence to the endothelium during inflammatory conditions. These effects may relate to purported effects of the statins on remodeling of the vessel wall,17 which may be partially due to enhanced NO generation. Thus, the statins may have important biological effects that promote endothelial preservation and vascular homeostasis independently of their cholesterol-lowering effects. These actions may have important applications in attenuating leukocyte-induced cell injury such as that occurring in reperfusion injury.
|
Acknowledgments |
|---|
This study was supported in part by research grant GM-45434 from the National Institutes of Health.
Received December 31, 1998; revision received March 18, 1999; accepted March 31, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Forman MB, Kolodgie FD, Jenkins M, Virmani R. Endothelial and myocardial injury during ischemia and reperfusion: pathogenesis and therapeutic implications. J Am Coll Cardiol. 1993;21:1245–1253.[Abstract]
2.
Tsao PS, Aoki N, Lefer DJ, Johnson G III, Lefer AM.
Time course of endothelial dysfunction and myocardial
injury during myocardial ischemia and reperfusion in the cat.
Circulation. 1990;82:1402–1412.
3. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW. Inflammation in the course of early myocardial ischemia. FASEB J. 1991;5:2529–2537.[Abstract]
4. Engler RL, Schmid-Schönbein GW, Pavlec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111:98–111.[Abstract]
5. Lefer AM, Tsao PS, Lefer DJ, Ma X-L. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 1991;5:2029–2034.[Abstract]
6. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365–376.[Medline] [Order article via Infotrieve]
7.
Buerke M, Weyrich AS, Lefer AM. Isolated cardiac
myocytes are sensitized by
hypoxia-reoxygenation to neutrophil released
mediators. Am J Physiol. 1994;266:H128–H136.
8.
Ma X-L, Lefer DJ, Lefer AM, Rothlein R.
Coronary endothelial and cardiac protective
effects of a monoclonal antibody to intercellular adhesion molecule-1
in myocardial ischemia and reperfusion. Circulation. 1992;86:937–946.
9.
Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA,
Lucchesi BR. Reduction of the extent of ischemic myocardial
injury by neutrophil depletion in the dog. Circulation. 1983;67:1016–1023.
10. Weyrich AS, Ma X-L, Lefer DJ, Albertine KH, Lefer AM. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 1993;91:2620–2629.
11.
Lefer AM, Weyrich AS, Buerke M. Role of selectins, a
new family of adhesion molecules, in ischaemia-reperfusion injury.
Cardiovasc Res. 1994;28:289–294.
12. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996;7:389–397.[Medline] [Order article via Infotrieve]
13.
Levine GN, Keaney JF Jr, Vita JA.
Cholesterol reduction in cardiovascular
disease. Clinical benefits and possible mechanisms. N Engl
J Med. 1995;332:512–521.
14.
Treasure CB, Klein JL, Weintraub WS, Talley JD,
Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC,
Alexander RW. Beneficial effects of cholesterol-lowering
therapy on the coronary endothelium in patients
with coronary artery disease. N Engl J
Med. 1995;332:481–487.
15.
Delanty N, Vaughan CJ. Vascular effects of statins in
stroke. Stroke. 1997;28:2315–2320.
16. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988;62:10J–15J.[Medline] [Order article via Infotrieve]
17. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079–1082.[Medline] [Order article via Infotrieve]
18.
Pabla R, Buda AJ, Flynn DM, Blesse SA, Shin AM, Curtis
MJ, Lefer DJ. Nitric oxide attenuates neutrophil-mediated myocardial
contractile dysfunction after ischemia and reperfusion.
Circ Res. 1996;78:65–72.
19. Lefer DJ, Scalia R, Campbell B, Nossuli TO, Hayward R, Salamon M, Grayson J, Lefer AM. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J Clin Invest. 1997;99:684–691.[Medline] [Order article via Infotrieve]
20. Williams JH Jr, Moser KM, Ulich T, Cairo MS. Harvesting the circulating pool of polymorphonuclear leukocytes by hetastarch exchange transfusion (HET): yield and function assessment. J Leuko Biol. 1987;42:455–462.[Abstract]
21.
Ma X-L, Weyrich AS, Lefer DJ, Buerke M, Albertine KH,
Kishimoto TK, Lefer AM. Monoclonal antibody to L-selectin attenuates
neutrophil accumulation and protects ischemic reperfused cat
myocardium. Circulation. 1993;88:649–658.
22.
Lefer AM, Campbell B, Scalia R, Lefer DJ. Synergism
between platelets and neutrophils in provoking cardiac dysfunction
after ischemia and reperfusion: role of selectins.
Circulation. 1998;98:1322–1328.
23.
Guo JP, Murohara T, Buerke M, Scalia R, Lefer AM.
Direct measurement of nitric oxide release from vascular
endothelial cells. J Appl Physiol. 1996;81:774–779.
24.
Osborne JA, Siegman MJ, Sedar AW, Mooers SU, Lefer AM.
Lack of endothelium-dependent relaxation in
coronary resistance arteries of cholesterol-fed
rabbits. Am J Physiol. 1989;256:C591–C597.
25.
Verbeuren TJ, Jordaens FH, Zoonekeyn LL, Van Hove CE,
Coene MC, Herman AG. Effect of
hypercholesterolemia on vascular reactivity in
the rabbit, I: endothelium-dependent and
endothelium-independent contractions and relaxations in
isolated arteries of control and hypercholesterolemic
rabbits. Circ Res. 1986;58:552–564.
26. Minor RL Jr, Myers PR, Guerra R Jr, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 1990;86:2109–2116.
27.
Stemerman MB. Effects of moderate
hypercholesterolemia on rabbit
endothelium.
Arteriosclerosis. 1981;1:25–32.
28. Lefer AM, Sedar AW. Endothelial alterations in hypercholesterolaemia and atherosclerosis. Pharmacol Res. 1991;23:1–12.[Medline] [Order article via Infotrieve]
29.
Tilton RG, Cole PA, Zions JD, Daugherty A, Larson KB,
Sutera SP, Kilo C, Williamson JR. Increased
ischemia-reperfusion injury to the heart associated with
short-term, diet-induced hypercholesterolemia
in rabbits. Circ Res. 1987;60:551–559.
30.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR,
Macfarlane PW, Mckillop JH, Packard CJ. Prevention of coronary
heart disease with pravastatin in men with
hypercholesterolemia. N Engl J
Med. 1995;333:1301–1307.
31. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest. 1989;83:465–473.
32. Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212–1217.[Abstract]
33.
Dunzendorfer S, Rothbucher D, Schratzberger P, Reinisch
N, Kahler CM, Wiedermann CJ. Mevalonate-dependent inhibition of
transendothelial migration and chemotaxis of human
peripheral blood neutrophils by pravastatin.
Circ Res. 1997;81:963–969.
34.
Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of
endothelial nitric oxide synthase by HMG CoA reductase
inhibitors. Circulation. 1998;97:1129–1135.
35.
Laufs U, La Fata V, Liao JK. Inhibition of
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks
hypoxia-mediated down-regulation of endothelial
nitric oxide synthase. J Biol Chem. 1997;272:31725–31729.
36.
Kubes P, Suzuki M, Granger D. Nitric oxide: an
endogenous modulator of leukocyte adhesion. Proc Natl
Acad Sci U S A. 1991;88:4651–4655.
37. Davenpeck KL, Gauthier TW, Lefer AM. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology. 1994;107:1050–1058.[Medline] [Order article via Infotrieve]
38. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest. 1995;96:60–68.
39.
Endres M, Laufs U, Huang Z, Nakamura T, Huang P,
Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl
(HMG)-CoA reductase inhibitors mediated by
endothelial nitric oxide synthase. Proc Natl Acad
Sci U S A. 1998;95:8880–8885.We studied the effects of
clinically relevant doses of simvastatin on
neutrophil-induced cardiac contractile dysfunction in isolated perfused
rat hearts subjected to ischemia-reperfusion.
Simvastatin-treated hearts exhibited markedly preserved
coronary flow, left ventricular developed pressure,
and left ventricular dP/dtmax during
reperfusion. Moreover, simvastatin-treated hearts
accumulated significantly fewer neutrophils after reperfusion, which
was associated with lower P-selectin expression on the coronary
endothelium. Finally, simvastatin
potentiated basal release of NO from the vascular
endothelium. Thus, simvastatin appears to
preserve cardiac function in the absence of
hypercholesterolemia by an NO-dependent
mechanism.
This article has been cited by other articles:
 |
|
 |
|
  C. Briguori, G. Visconti, A. Focaccio, B. Golia, A. Chieffo, A. Castelli, M. Mussardo, M. Montorfano, B. Ricciardelli, and A. Colombo Novel Approaches for Preventing or Limiting Events (Naples) II Trial: Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction J. Am. Coll. Cardiol., August 5, 2009; (2009) j.jacc.2009.07.005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Calvert and D. J. Lefer Myocardial protection by nitrite Cardiovasc Res, July 15, 2009; 83(2): 195 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Isma, J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia Angiology, October 1, 2008; 59(5): 542 - 548. [Abstract] [PDF]
|
|
|
|
 |
|
 L. S. FELDMAN and D. J. BROTMAN Perioperative statins: More than lipid-lowering? Cleveland Clinic Journal of Medicine, September 1, 2008; 75(9): 654 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Zoghbi, T. A. Dorfman, and A. E. Iskandrian The Effects of Medications on Myocardial Perfusion J. Am. Coll. Cardiol., August 5, 2008; 52(6): 401 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yin, J. Zhu, Z. Wang, H. Huang, J. Qian, Z. Li, and H. Jing Simvastatin attenuates cardiac isograft ischemia-reperfusion injury by down-regulating CC chemokine receptor-2 expression J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 780 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. M. Greer, A. K. Kakkar, J. W. Elrod, L. J. Watson, S. P. Jones, and D. J. Lefer Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2743 - H2751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Collard, S. C. Body, S. K. Shernan, S. Wang, D. T. Mangano, and Multicenter Study of Perioperative Ischemia (MCSPI Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 392 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Cohen, X.-M. Yang, and J. M. Downey Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies Cardiovasc Res, May 1, 2006; 70(2): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Pascual, J. M. Arribas, P. L. Tornel, F. Marin, C. Oliver, M. Ahumada, J. Gomez-Plana, P. Martinez, R. Arcas, and M. Valdes Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery Ann. Thorac. Surg., January 1, 2006; 81(1): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Murata, K. Kinoshita, M. Hori, M. Kuwahara, H. Tsubone, H. Karaki, and H. Ozaki Statin Protects Endothelial Nitric Oxide Synthase Activity in Hypoxia-Induced Pulmonary Hypertension Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2335 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Laufs and M. Bohm Cardiac effects of statins-advancements and open questions Cardiovasc Res, June 1, 2005; 66(3): 427 - 429. [Full Text] [PDF]
|
|
|
|
|
|
P. Di Napoli, A. A. Taccardi, A. Grilli, M. A. De Lutiis, A. Barsotti, M. Felaco, and R. De Caterina Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts Cardiovasc Res, June 1, 2005; 66(3): 462 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, T. Asagami, H. Matsushita, K.-H. Lee, and P. S. Tsao Rosuvastatin Attenuates Monocyte-Endothelial Cell Interactions and Vascular Free Radical Production in Hypercholesterolemic Mice J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 557 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mensah, M. M. Mocanu, and D. M. Yellon Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1287 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanada, H. Asanuma, T. Minamino, K. Node, S. Takashima, H. Okuda, Y. Shinozaki, A. Ogai, M. Fujita, A. Hirata, et al. Optimal Windows of Statin Use for Immediate Infarct Limitation: 5'-Nucleotidase as Another Downstream Molecule of Phosphatidylinositol 3-Kinase Circulation, October 12, 2004; 110(15): 2143 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Pan, T. Pintar, J. Anton, V.-V. Lee, W. K. Vaughn, and C. D. Collard Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery Circulation, September 14, 2004; 110(11_suppl_1): II-45 - II-49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lazar Role of statin therapy in the coronary bypass patient Ann. Thorac. Surg., August 1, 2004; 78(2): 730 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Spencer, J. Allegrone, R. J. Goldberg, J. M. Gore, K. A.A. Fox, C. B. Granger, R. H. Mehta, D. Brieger, and the GRACE Investigators* Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study Ann Intern Med, June 1, 2004; 140(11): 857 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miyahara, J. Kiryu, K. Yamashiro, K. Miyamoto, F. Hirose, H. Tamura, H. Katsuta, K. Nishijima, A. Tsujikawa, and Y. Honda Simvastatin Inhibits Leukocyte Accumulation and Vascular Permeability in the Retinas of Rats with Streptozotocin-Induced Diabetes Am. J. Pathol., May 1, 2004; 164(5): 1697 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tailor, D. J. Lefer, and D. N. Granger HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1402 - H1407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.M Sacks Do statins play a role in the early management of the acute coronary syndrome? Eur. Heart J. Suppl., March 1, 2004; 6(suppl_A): A32 - A36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schulz, M. Kelm, and G. Heusch Nitric oxide in myocardial ischemia/reperfusion injury Cardiovasc Res, February 15, 2004; 61(3): 402 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Galinanes and A. G Fowler Role of clinical pathologies in myocardial injury following ischaemia and reperfusion Cardiovasc Res, February 15, 2004; 61(3): 512 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pierre-Paul and V. Gahtan Noncholesterol-Lowering Effects of Statins Vascular and Endovascular Surgery, September 1, 2003; 37(5): 301 - 313. [Abstract] [PDF]
|
|
|
|
|
|
M. Chello, P. Mastroroberto, G. Frati, G. Patti, A. D'Ambrosio, G. Di Sciascio, and E. Covino Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft Ann. Thorac. Surg., August 1, 2003; 76(2): 453 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Naidu, S. M. Woolley, A. S. Farivar, R. Thomas, C. Fraga, and M. S. Mulligan Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 482 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Tiefenbacher, J. Kapitza, V. Dietz, C.-H. Lee, and F. Niroomand Reduction of myocardial infarct size by fluvastatin Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H59 - H64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lazar, Y. Bao, Y. Zhang, and S. A. Bernard Pretreatment with statins enhances myocardial protection during coronary revascularization J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1037 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Chello, P Mastroroberto, G Patti, A D'Ambrosio, M C. Morichetti, G Di Sciascio, and E Covino Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass Heart, May 1, 2003; 89(5): 538 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sasaki, S. Bharwani, P. Jordan, T. Joh, K. Manas, A. Warren, H. Harada, P. Carter, J. W. Elrod, M. Wolcott, et al. The 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitor Pravastatin Reduces Disease Activity and Inflammation in Dextran-Sulfate Induced Colitis J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 78 - 85. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Bell and D. M. Yellon Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway J. Am. Coll. Cardiol., February 5, 2003; 41(3): 508 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gertz, U. Laufs, U. Lindauer, G. Nickenig, M. Bohm, U. Dirnagl, and M. Endres Withdrawal of Statin Treatment Abrogates Stroke Protection in Mice Stroke, February 1, 2003; 34(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Skaletz-Rorowski, M. Lutchman, Y. Kureishi, D. J. Lefer, J. R. Faust, and K. Walsh HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells Cardiovasc Res, January 1, 2003; 57(1): 253 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Di Napoli, A.A. Taccardi, M. Oliver, and R. De Caterina Statins and stroke: evidence for cholesterol-independent effects Eur. Heart J., December 2, 2002; 23(24): 1908 - 1921. [PDF]
|
|
|
|
 |
|
 M. Honjo, H. Tanihara, K. Nishijima, J. Kiryu, Y. Honda, B. Y. J. T. Yue, and T. Sawamura Statin Inhibits Leukocyte-Endothelial Interaction and Prevents Neuronal Death Induced by Ischemia-Reperfusion Injury in the Rat Retina Arch Ophthalmol, December 1, 2002; 120(12): 1707 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lefer Statins as Potent Antiinflammatory Drugs Circulation, October 15, 2002; 106(16): 2041 - 2042. [Full Text] [PDF]
|
|
|
|
|
|
D. Pruefer, J. Makowski, M. Schnell, U. Buerke, M. Dahm, H. Oelert, U. Sibelius, U. Grandel, F. Grimminger, W. Seeger, et al. Simvastatin Inhibits Inflammatory Properties of Staphylococcus aureus{alpha}-Toxin Circulation, October 15, 2002; 106(16): 2104 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Sposito and M. J. Chapman Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1524 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Li, H. Chen, F. Romeo, T. Sawamura, T. Saldeen, and J. L. Mehta Statins Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1 J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 601 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Iraculis, A. Cequier, J. A. Gomez-Hospital, M. Sabate, J. Mauri, E. Fernandez-Nofrerias, B. Garcia del Blanco, F. Jara, and E. Esplugas Early dysfunction and long-term improvement in endothelium-dependent vasodilation in the infarct-related artery after thrombolysis J. Am. Coll. Cardiol., July 17, 2002; 40(2): 257 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rezaie-Majd, T. Maca, R. A. Bucek, P. Valent, M. R. Muller, P. Husslein, A. Kashanipour, E. Minar, and M. Baghestanian Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1194 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-D. Wang, J. Pernow, P.-O. Sjoquist, and L. Ryden Pharmacological possibilities for protection against myocardial reperfusion injury Cardiovasc Res, July 1, 2002; 55(1): 25 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shiojima and K. Walsh Role of Akt Signaling in Vascular Homeostasis and Angiogenesis Circ. Res., June 28, 2002; 90(12): 1243 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Palinski and S. Tsimikas Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1673 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gao, C.-L. Yao, E. Gao, Q.-Z. Mo, W.-L. Yan, R. McLaughlin, B. L. Lopez, T. A. Christopher, and X. L. Ma Enhancement of Glutathione Cardioprotection by Ascorbic Acid in Myocardial Reperfusion Injury J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler Double-Edged Role of Statins in Angiogenesis Signaling Circ. Res., April 5, 2002; 90(6): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ikeda, L. H. Young, and A. M. Lefer Attenuation of neutrophil-mediated myocardial ischemia-reperfusion injury by a calpain inhibitor Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1421 - H1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Jones, S. D. Trocha, and D. J. Lefer Pretreatment With Simvastatin Attenuates Myocardial Dysfunction After Ischemia and Chronic Reperfusion Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 2059 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Katoh, Y. Kurosawa, K. Tanaka, A. Watanabe, H. Doi, and H. Narita Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H655 - H660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Di Napoli, A. Antonio Taccardi, A. Grilli, R. Spina, M. Felaco, A. Barsotti, and R. De Caterina Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts Cardiovasc Res, August 1, 2001; 51(2): 283 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Young, Y. Ikeda, and A. M. Lefer Caveolin-1 peptide exerts cardioprotective effects in myocardial ischemia-reperfusion via nitric oxide mechanism Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2489 - H2495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pernow, A.T. Gonon, and A. Gourine The role of the endothelium for reperfusion injury Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C22 - C27. [Abstract] [PDF]
|
|
|
|
|
|
R. Scalia, M. E. Gooszen, S. P. Jones, M. Hoffmeyer, D. M. Rimmer III, S. D. Trocha, P. L. Huang, M. B. Smith, A. M. Lefer, and D. J. Lefer Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E-Deficient Mice Circulation, May 29, 2001; 103(21): 2598 - 2603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Engelhardt, B. H. Cuthbertson, B. Lindahl, and L. Wallentin Markers of Myocardial Damage and Inflammation in Unstable Coronary Artery Disease N. Engl. J. Med., March 1, 2001; 344(9): 688 - 689. [Full Text] [PDF]
|
|
|
|
|
|
A. M Lefer, R. Scalia, and D. J Lefer Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease Cardiovasc Res, February 1, 2001; 49(2): 281 - 287. [Full Text] [PDF]
|
|
|
|
|
|
W. Palinsk New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Sparrow, C. A. Burton, M. Hernandez, S. Mundt, H. Hassing, S. Patel, R. Rosa, A. Hermanowski-Vosatka, P.-R. Wang, D. Zhang, et al. Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ikeda, L. H Young, R. Scalia, C. R Ross, and A. M Lefer PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion Cardiovasc Res, January 1, 2001; 49(1): 69 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Laufs, M. Endres, F. Custodis, K. Gertz, G. Nickenig, J. K. Liao, and M. Bohm Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription Circulation, December 19, 2000; 102(25): 3104 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mital, X. Zhang, G. Zhao, R. D. Bernstein, C. J. Smith, D. L. Fulton, W. C. Sessa, J. K. Liao, and T. H. Hintze Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2649 - H2657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Young, Y. Ikeda, R. Scalia, and A. M. Lefer Wortmannin, a Potent Antineutrophil Agent, Exerts Cardioprotective Effects in Myocardial Ischemia/Reperfusion J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 37 - 43. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. W. Fenton, G. X. Shen, F. L. Minnear, D. V. Brezniak, J. M. Walenga, J. J. Bognacki, and F. A. Ofosu State-of-the-Art-Review : Statins Induce Hypothrombotic States? Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 18 - 21. [Abstract] [PDF]
|
|
|
|
|
|
D. Pruefer, R. Scalia, and A. M. Lefer Simvastatin Inhibits Leukocyte-Endothelial Cell Interactions and Protects Against Inflammatory Processes in Normocholesterolemic Rats Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2894 - 2900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hayashidani, H. Tsutsui, T. Shiomi, N. Suematsu, S. Kinugawa, T. Ide, J. Wen, and A. Takeshita Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction Circulation, February 19, 2002; 105(7): 868 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler Double-Edged Role of Statins in Angiogenesis Signaling Circ. Res., April 5, 2002; 90(6): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||